CD270 (TNFRSF14) polyclonal, anti-human

Protein Family: Cellular Antigens, Receptors and Channels

Pathway and Disease: Immune System, Infectious Diseases, Signaling Molecules and Interaction

Description:
Tumor necrosis factor receptor (TNFR) superfamily members are defined by cysteine-rich domains in their extracellular regions that bind TNF-related ligands that share a common structural homology in their extracellular domain. TNFRSF14 was initially identified as the Herpesvirus entry mediator and upon binding to the herpes simplex virus (HSV) envelope glycoprotein D or either of its natural ligands LIGHT and lymphotoxin alpha (LT), activates the transcription factors NF-kappaB and AP-1. Activation of this signal transduction pathway in T cells stimulates T cell proliferation and cytokine production, leading to inflammation and enhanced CTL-mediated tumor immunity, suggesting that these proteins may be useful as potential targets for controlling cellular immune responses.

Alternate Names: TNFRSF14 , Tumor necrosis factor receptor superfamily member 14, Herpes virus entry mediator A, HVEM, TR2, ATAR, HVEA, HVEM, CD270, LIGHTR

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; ICC: 1:100-1:500; IF: 1:50-1:200

Accession No.: Q92956

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human TNFRSF14.

Format: Each vial contains 0.1 ml IgG (1 mg/ml) in PBS pH 7.4 with 0.02% sodium azide. Antibody was purified by immunogen affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.